CN101574424B - Application of medicine combination in preparing medicament with function of protecting pancreatic island - Google Patents
Application of medicine combination in preparing medicament with function of protecting pancreatic island Download PDFInfo
- Publication number
- CN101574424B CN101574424B CN 200810052992 CN200810052992A CN101574424B CN 101574424 B CN101574424 B CN 101574424B CN 200810052992 CN200810052992 CN 200810052992 CN 200810052992 A CN200810052992 A CN 200810052992A CN 101574424 B CN101574424 B CN 101574424B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- pharmaceutical composition
- rhizoma
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 241000207929 Scutellaria Species 0.000 claims abstract description 6
- 230000014509 gene expression Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 19
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 108010052621 fas Receptor Proteins 0.000 claims description 15
- 102000018823 fas Receptor Human genes 0.000 claims description 15
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 14
- 230000006870 function Effects 0.000 claims description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 6
- 230000003915 cell function Effects 0.000 claims description 5
- 235000008216 herbs Nutrition 0.000 claims description 5
- 230000003313 weakening effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 3
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 abstract 1
- 235000016646 Citrus taiwanica Nutrition 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 210000004153 islets of langerhan Anatomy 0.000 description 16
- 239000000843 powder Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000008517 radix Trichosanthis Substances 0.000 description 13
- 239000006071 cream Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- -1 electuary Substances 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 239000012567 medical material Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 229940032147 starch Drugs 0.000 description 10
- 238000001291 vacuum drying Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003390 Chinese drug Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 8
- 102000051325 Glucagon Human genes 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 7
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 7
- 229960004666 glucagon Drugs 0.000 description 7
- 230000002055 immunohistochemical effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 235000020925 non fasting Nutrition 0.000 description 4
- 210000004923 pancreatic tissue Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001522129 Pinellia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of medicine combination in preparing medicament with the function of protecting pancreatic island. The medicine combination comprises the following raw medicinal materials by weight portion: 3-30 of bupleurum, 3-15 of peony roots, 3-15 of citrus aurantium, 1-6 of rhubarb, 3-15 of scutellaria and 1-12 of coptis roots.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to the application of a kind of pharmaceutical composition in the medicine of preparation treatment diabetes.
Background technology
Diabetes are the lifelong diseases of a kind of chronic progressive external that caused by sugar, protein and fat metabolic disturbance in body, and its characteristic shows as hyperglycemia and glycosuria.This disease will cause heart and renal complication, blind and amputation.From observing clinically, the sickness rate of diabetes is being ascendant trend year by year in recent years.At present, approximately there are 1.5 hundred million diabeticss in the whole world, and the current diabetes number of China surpasses 4,000 ten thousand.In diabetes cases, minority is insulin dependent diabetes mellitus (IDDM) (I type), and great majority are non-insulin-dependent diabetes mellitus (II type).Most diabetics need to be taken medicine all the life.
Once type ii diabetes occurs, islet function is lasting degradation trend, finally causes islet cells exhaustion.Along with the exhaustion gradually of islet beta cell function, passive selection medicine is controlled the method for blood glucose to traditional type ii diabetes therapeutic scheme as far as possible, not only can not be fine control patient's blood glucose but also inevitable islet beta cell function exhaustion and develop complications in early days.Therefore, at type ii diabetes, find in early days the protection islets of langerhans, the medicine or the prophylactico-therapeutic measures that recover the regulatory function of islets of langerhans self become the focus in current diabetes study.
The Fas system that Fas antigen and FasL (Fas-L) form, be by apoptotic signal forward to into intracellular Major Systems it, account for consequence in autoimmune disease.Fas-L in conjunction with Fas antigen after, Fas antigen conducts apoptotic signal in cell, within a few hours, by apoptotic pathways, makes target cell death.Think that at present the expression of Fas antigen is relevant with the generation of diabetes; Wilma etc. by the islet cell transplantation of diabetic mice and euglycemia Mus to the NOD Mus, apply double-colored Immunohistochemical Method and analyze the expression of FasL and Fas in mouse islets, find that FasL is at CD4+, the CD8+T lymphocyte reaches from the β cellular expression of euglycemia Mus and diabetic mice transplanting, Fas is at CD4+, CD8+T lymphocyte and the β cellular expression of transplanting from diabetic mice, euglycemia Mus β cell does not express Fas or expression is very low, there were significant differences for the two, and it is extremely low that pcr analysis also proves that FasmRNA expresses in the euglycemia Mus.Therefore the expression of Fas-L can be organized protective effect to insulin.
Treating diabetes still be take chemical synthetic drug as main at present, as sulfonamides, biguanides, glucosidase inhibitor, Lie Nai and euglycemic agent etc.But these medicine long-term taking side effect are all larger.
Chinese medicine has long history preventing and treating aspect diabetes, and the practice through several thousand, accumulated a large amount of invaluable experiences, formed unique Scientific systems.Treatment is with the dissipating depression of QI clearing stomach, nourishing YIN to lower pathogenic fire, and purging FU-organs rushes down turbid.The Chinese medicine ancient books and records have been put down in writing the Chinese medicine that much has the blood sugar lowering curative effect, as Rhizoma Alismatis, the Rhizoma Anemarrhenae, Radix Panacis Quinquefolii, Radix Puerariae, Radix Rehmanniae, pollen etc.
Summary of the invention
The application of the invention provides-kind of pharmaceutical composition in preparation protection islet function medicine.
The effect of pharmaceutical composition protection islet function of the present invention is to have protected islet beta cell function.
The mechanism of pharmaceutical composition protection islet beta cell function of the present invention is to weaken the expression of Fas antigen, strengthens the expression of FasL.
The raw medicinal herbs that pharmaceutical composition of the present invention contains following weight portion: Radix Bupleuri 3-30 part, Radix Paeoniae Alba 3-15 part, Fructus Aurantii Immaturus 3-15 part, Radix Et Rhizoma Rhei 1-6 part, Radix Scutellariae 3-15 part, Rhizoma Coptidis 1-12 part.Be preferably 9 parts of Radix Bupleuri, 15 parts of the Radix Paeoniae Albas, 9 parts of Fructus Aurantii Immaturuss, 3 parts of Radix Et Rhizoma Rhei, 9 parts of Radix Scutellariaes, 5 parts of Rhizoma Coptidis.
Can also add Radix Trichosanthis, the Rhizoma Pinelliae, Fructus Mume in order to obtain better effect.Each raw medicinal herbs weight portion is respectively: Radix Trichosanthis 5-40 part, Radix Bupleuri 10-30 part, Fructus Aurantii Immaturus 3-15 part, Radix Et Rhizoma Rhei 1-6 part, Rhizoma Pinelliae 1-12 part, Radix Scutellariae 3-15 part, Rhizoma Coptidis 1-12 part, Radix Paeoniae Alba 3-15 part, Fructus Mume 5-20 part.Be preferably: 9 parts of Radix Trichosanthis, 12 parts of Radix Bupleuri, 9 parts of Fructus Aurantii Immaturuss, 3 parts of Radix Et Rhizoma Rhei, 6 parts of the Rhizoma Pinelliaes, 9 parts of Radix Scutellariaes, 6 parts of Rhizoma Coptidis, 9 parts of the Radix Paeoniae Albas, 9 parts of Fructus Mumes.
Better, the present invention can also add Fructus Crataegi on the basis of described medicine, and this is because the Fructus Crataegi sour and sweet drugs can transforme into YIN, both can be in case hot loose too impairment of YIN, but picric acid system is sweet again.The heat clearing away of compatibility dissipating depression of QI has good curative effect.The weight portion of each raw medicinal herbs is: Radix Trichosanthis 5-40 part, Radix Bupleuri 10-30 part, Fructus Aurantii Immaturus 3-15 part, Radix Et Rhizoma Rhei 1-6 part, Rhizoma Pinelliae 1-12 part, Radix Scutellariae 3-15 part, Rhizoma Coptidis 1-12 part, Radix Paeoniae Alba 3-15 part, Fructus Mume 5-20 part, Fructus Crataegi 3-15 part.Be preferably: Radix Trichosanthis 10-30 part, Radix Bupleuri 10-30 part, Fructus Aurantii Immaturus 3-15 part, Radix Et Rhizoma Rhei 1-6 part, Rhizoma Pinelliae 1-12 part, Radix Scutellariae 3-15 part, Rhizoma Coptidis 1-12 part, Radix Paeoniae Alba 3-15 part, Fructus Mume 5-20 part, Fructus Crataegi 3-15 part.More preferably: 30 parts of Radix Trichosanthis, 12 parts of Radix Bupleuri, 9 parts of Fructus Aurantii Immaturuss, 3 parts of Radix Et Rhizoma Rhei, 6 parts of the Rhizoma Pinelliaes, 9 parts of Radix Scutellariaes, 6 parts of Rhizoma Coptidis, 9 parts of the Radix Paeoniae Albas, 15 parts of Fructus Mumes, 9 parts of Fructus Crataegis; Perhaps 15 parts of Radix Trichosanthis, 12 parts of Radix Bupleuri, 9 parts of Fructus Aurantii Immaturuss, 3 parts of Radix Et Rhizoma Rhei, 6 parts of the Rhizoma Pinelliaes, 9 parts of Radix Scutellariaes, 6 parts of Rhizoma Coptidis, 9 parts of the Radix Paeoniae Albas, 15 parts of Fructus Mumes, 9 parts of Fructus Crataegis.
Pharmaceutical composition of the present invention makes by following steps:
(1) described medical material adds the water reflux, extract; Extracting liquid filtering, concentrating under reduced pressure;
(2) concentrated solution adds ethanol to being 65-75% containing the alcohol amount, filters;
(3) filtrate decompression is condensed into extractum, and vacuum drying is made dried cream powder;
(4) in dried cream powder, add adjuvant to make acceptable dosage form on medicament.
In described step (1), preferably add water reflux, extract, twice, the water of each 10 times of its weight, each 1.5 hours.
In described step (1), preferably extracting solution is concentrated into 1: 1 (ratio of initial medical material weight and the volume of concentrated solution).In described step (2), the concentration of alcohol added is preferably 90-100%, and more preferably 95%.Be preferably 70% containing the alcohol amount.
Pharmaceutical composition of the present invention can add pharmaceutically acceptable adjuvant, also can add other drug to make together compound formulation.
Pharmaceutical composition of the present invention, be the pharmaceutical dosage forms of unit dose, and described unit dosage form refers to the unit of preparation, as every of tablet, and every capsules of capsule, every bottle of oral liquid, every bag of granule etc.
Compositions of the present invention active component wherein, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.
Compositions of the present invention, by being mixed with above-mentioned active component and medicine acceptable carrier to obtain.
Compositions of the present invention, its pharmaceutical dosage forms can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.; And injection, as: injectable powder, injection, transfusion etc.
Compositions of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
Applicable filler comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of suitable medicine comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Repeatedly mix and can make active substance be distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid can be for example aqueous or oily suspensions, solution, Emulsion, syrup or elixir, or can be a kind of available water before use or the composite dry products of other suitable carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if need, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this compound can be suspended or dissolve.The preparation of solution is normally by active substance being dissolved in a kind of carrier, and filter-sterilized before it is packed into a kind of suitable bottle or ampoule, then seal.Adjuvant for example a kind of local anesthetic, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into, that this compositions is freezing, and under vacuum, water is removed.
Compositions of the present invention, optionally add applicable medicine acceptable carrier when being prepared into medicament, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is determined usage and dosage according to patient's situation in use, but takes every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The present invention illustrates application of the present invention by following experimental data.
The impact of the test example present composition on streptozotocin diabetes rats pancreatic tissue Fas system expression
1. materials and methods
1.1 animal
Select male Wistar rat, body weight 180-220g, in 6-8 week in age week, provided by Chinese Academy of Medical Sciences's Experimental Animal Center.Be divided at random 4 groups: one group is Normal group, and another three groups first are prepared into diabetes model, then are divided into diabetic model group, Chinese drug-treated group and Western medicine group.The diabetes model preparation method: fasting is after 12 hours, left lower quadrant intraperitoneal injection STZ (with in 0.1mol/l citric acid-sodium citrate buffer ice bath, being mixed with 1% solution, pH value 4.4) 65mg/kg body weight.Survey blood glucose after three days and be defined as diabetes the above person of 16.7mmol/l; Rats in normal control group intraperitoneal injection equal-volume citrate buffer solution.
1.2 medicine and instrument
Medicine: the embodiment of the present invention 1 granule is mixed with the solution containing crude drug 4g/ml; Metformin hydrochloride tablet: is produced from Beijing Double-Crane Pharmaceutical Co., Ltd, lot number: 990825; Streptozotocin (Streptozotocin STZ): purchased from Sigma company, lot number 202-263-7; Insulin, glucagon radioimmunoassay kits: the sharp biotechnology center product of Beijing sea section, lot number is respectively defends the accurate word R-11 of medicine, R-64.
Instrument: one-touch II blood glucose meter: Johnson Co.'s product.
1.3 experimental technique
Medication: each group is 1. Chinese drug-treated group of gastric infusion surrounding: the embodiment of the present invention 1 granule 36g/kg is the Western medicine group 2.: metformin 0.5g/kg is model group 3.: normal saline 3ml/ is 4. Normal group only: normal saline 3ml/ only.
Blood glucose: the tail venous blood sampling, while before administration, reaching administration second, surrounding, each is surveyed once.
1.4 serum insulin, glucagon are measured: after the pentobarbital sodium anesthesia of animal 35mg/kg, the carotid artery intubate is got blood; After standing 1h, centrifugal serum (3500rpm) 10min; With radioimmunoassay for detecting (pressing the operation of medicine box description step).
1.5 the immunohistochemical observation of pancreatic tissue Fas receptor and Fas-L part:
Each treated animal sacrificed by exsanguination, get pancreas conventional fixing, paraffin embedding, the thick section of 5 μ m.The expression that shows islets of langerhans Fas and Fas-L with the immunohistochemical ABC Faxian, anti-(the anti-Fas of rabbit and Fas-L polyclonal antibody) II of agents useful for same I anti-(the anti-rabbit igg of biotinylated goat), III anti-(Radix Cochleariae officinalis enzyme labelling chain enzyme avidin) and developer series are Beijing Zhong Shan company product.The immunohistochemical staining process is as follows: paraffin section de-waxing is to water → 3%H
20
2incubated at room 10 minutes, to eliminate the activity → distilled water flushing of endogenous peroxydase, 5 minutes → 10% normal goats serum sealing (PBS dilution) of PBS immersion bubble, incubated at room 10 minutes → serum deprivation inclines, drip respectively Fas and Fas-L antibody working solution, putting 4 ℃ of refrigerator overnight → PBS in wet box rinses, 5 minutes * 3 times → drip II to resist, 37 ℃ of temperature are incubated 30 minutes, PBS rinses, 5 minutes * 3 times, drip the Radix Cochleariae officinalis enzyme labelling chain enzyme avidin of 1: 200, 30 minutes → PBS of 37 ℃ of incubations rinses, fully rinse → haematoxylin redyeing of 5 minutes * 3 times → DAB colour developing → tap water, tap water rinses more than 15 minutes → transparent → gummy mounting of dehydration of alcohol → dimethylbenzene step by step.Under light microscopic, observe.1.6 the statistical procedures experimental data means by mean ± standard deviation, significant difference employing t check between group.
2. result
2.1 the impact on the non-fasting glucose of STZ rat
Model group blood glucose compared with normal group obviously raises (P<0.001), after treating 4 weeks, Chinese medicine and metformin all can make blood glucose descend (P<0.01 >.In Table 1.
Table 1 is respectively organized non-fasting glucose relatively
Annotate: with the normal group ratio
△ △ △p<0.001, with the model group ratio
*p<0.05;
*p<0.01
2.2 the impact on STZ rat insulin, glucagon
Model group glucagon content rising (P<0.001); Insulin content reduces (P<0.001).After treatment with the model group ratio: Chinese drug-treated group and metformin group all have no significant effect insulin and glucagon content.In Table 2.
Table 2 is respectively organized the comparison of insulin, glucagon variation
Annotate: with the normal group ratio
△ △ △p<0.001,
△ △p<0.01,
△p<0.05, with the model group ratio
*p<0.05
2.3 the immunohistochemical observation of pancreas in rat cell Fas antigen and FasL
2.3.1Fas antigen
Normal group: the visible light brown granule of minute quantity cell in islets of langerhans, become faint expression, most cells are negative.(accompanying drawing 1)
Model group: the islets of langerhans inner cell is the product of brownish red positive reaction widely as seen, and the strong positive that slabbing distributes is expressed.(accompanying drawing 2)
The Western medicine group: the islets of langerhans inner cell is brown positive reaction product widely as seen, the medium positive expression that slabbing distributes.(accompanying drawing 3)
Chinese drug-treated group: in islets of langerhans, the cell of positive expression is dispersed in distribution, and product is light brown.(accompanying drawing 4) 2.3.2Fas part
Normal group: the FasL expression that is negative in islets of langerhans.(accompanying drawing 5)
Model group: the visible light brown granule of minute quantity cell in islets of langerhans becomes faint expression.(accompanying drawing 6)
The Western medicine group: the islets of langerhans inner cell is brown positive reaction product widely as seen, and slabbing distributes, and medium-strong positive is expressed.(accompanying drawing 7)
Chinese drug-treated group: the islets of langerhans inner cell is brown positive reaction product widely as seen, and slabbing distributes, and medium-strong positive is expressed.(accompanying drawing 8)
3. conclusion
Find in this experiment that muroid is on an empty stomach after 12 hours, each organizes blood glucose and normal group without obvious difference, so this research is observed the impact of this medicine on blood glucose by non-fasting glucose.Chinese medicine starts just to have significantly to fall non-fasting glucose effect in administration in 2 weeks; Each group without the effect improved, illustrates that its blood sugar reducing function, by insulin-mediated, is different from sulphanylureas to insulin concentration and glucagon.This illustrates that its blood sugar reducing function mechanism is to increase insulin sensitivity.
In the STZ diabetes rat model, due to the toxic action of streptozotocin to pancreatic tissue, islet function is badly damaged.This result of study shows: normal group Fas antigen is negative expression in most cells; A small amount of cell is faint expression, and model group is strong positive and expresses.The expression that Fas antigen after occurrence of diabetes is described strengthens, and shows that Intra-islet Apoptosis strengthens.Chinese medicine and Western medicine group all can make the expression of Fas antigen weaken, and have suppressed immunoreactive process in islets of langerhans after oral Chinese medicine is described.FasL expressions that be negative in the normal group islets of langerhans, model forms faint expression, and the Western medicine group all becomes medium-strong positive expression with Chinese drug-treated group.Further proved Chinese medicine can play a protective role to pancreatic tissue, thereby delays the exhaustion of islet cells.
The accompanying drawing explanation
Fig. 1 is normal rats pancreatic cell Fas antigen immune group observation figure, HE*400
Fig. 2 is model group pancreas in rat cell Fas antigen immune group observation figure, HE*400
Fig. 3 is Western medicine group pancreas in rat cell Fas antigen immune group observation figure, HE*400
Fig. 4 is Chinese drug-treated group pancreas in rat cell Fas antigen immune group observation figure, HE*400
Fig. 5 is normal rats pancreatic cell FasL immunohistochemical observation figure, HE*400
Fig. 6 is model group pancreas in rat cell FasL immunohistochemical observation figure, HE*400
Fig. 7 is Western medicine group pancreas in rat cell FasL immunohistochemical observation figure, HE*400
Fig. 8 is Chinese drug-treated group pancreas in rat cell FasL immunohistochemical observation figure, HE*400
The specific embodiment
Below by concrete embodiment, application of the present invention is described further, but not as limitation of the present invention.
Embodiment 1
Radix Bupleuri 600g, Radix Paeoniae Alba 600g, Fructus Aurantii Immaturus 600g, Radix Et Rhizoma Rhei 200g, Radix Scutellariae 600g, Rhizoma Coptidis 200g
6 flavors, 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 90% ethanol to containing alcohol amount 65%, filters, and concentrating under reduced pressure becomes thick paste.75 ℃ of vacuum dryings, make dried cream powder.
Embodiment 2
Radix Bupleuri 600g, Radix Paeoniae Alba 600g, Fructus Aurantii Immaturus 600g, Radix Et Rhizoma Rhei 240g, Radix Scutellariae 600g, Rhizoma Coptidis 480g
6 flavors, 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds dehydrated alcohol to containing alcohol amount 75%, filters, and concentrating under reduced pressure becomes thick paste.85 ℃ of vacuum dryings, make dried cream powder.
Embodiment 3
Radix Bupleuri 540g, Radix Paeoniae Alba 900g, Fructus Aurantii Immaturus 540g, Radix Et Rhizoma Rhei 180g, Radix Scutellariae 540g, Rhizoma Coptidis 300g
6 flavors, 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 95% ethanol to containing alcohol amount 70%, filters, and concentrating under reduced pressure becomes thick paste.80 ℃ of vacuum dryings, make dried cream powder.
Embodiment 4
Radix Trichosanthis 750g, Radix Bupleuri 1500g, Fructus Aurantii Immaturus 450g, Radix Et Rhizoma Rhei 150g, Rhizoma Pinelliae 150g, Radix Scutellariae 450g, Rhizoma Coptidis 150g, Radix Paeoniae Alba 450g, Fructus Mume 750g
9 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 90% ethanol to containing alcohol amount 65%, filters, and concentrating under reduced pressure becomes thick paste.80 ℃ of vacuum dryings, make dried cream powder.
Embodiment 5
Radix Trichosanthis 1200g, Radix Bupleuri 900g, Fructus Aurantii Immaturus 450g, Radix Et Rhizoma Rhei 180g, Rhizoma Pinelliae 360g, Radix Scutellariae 450g, Rhizoma Coptidis 360g, Radix Paeoniae Alba 450g, Fructus Mume 600g
9 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds dehydrated alcohol to containing alcohol amount 75%, filters, and concentrating under reduced pressure becomes thick paste.85 ℃ of vacuum dryings, make dried cream powder.
Embodiment 6
Radix Trichosanthis 630g, Radix Bupleuri 840g, Fructus Aurantii Immaturus 630g, Radix Et Rhizoma Rhei 210g, Rhizoma Pinelliae 420g, Radix Scutellariae 630g, Rhizoma Coptidis 420g, Radix Paeoniae Alba 630g, Fructus Mume 630g
9 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 95% ethanol to containing alcohol amount 70%, filters, and concentrating under reduced pressure becomes thick paste.75 ℃ of vacuum dryings, make dried cream powder.
Embodiment 7
Radix Trichosanthis 750g, Radix Bupleuri 1500g, Fructus Aurantii Immaturus 450g, Radix Et Rhizoma Rhei 150g, Rhizoma Pinelliae 150g, Radix Scutellariae 450g, Rhizoma Coptidis 150g, Radix Paeoniae Alba 450g, Fructus Mume 750g, Fructus Crataegi 450g
10 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 95% ethanol to containing alcohol amount 70%, filters, and concentrating under reduced pressure becomes thick paste.85 ℃ of vacuum dryings, make dried cream powder.
Embodiment 8
Radix Trichosanthis 1200g, Radix Bupleuri 800g, Fructus Aurantii Immaturus 600g, Radix Et Rhizoma Rhei 200g, Rhizoma Pinelliae 400g, Radix Scutellariae 400g, Rhizoma Coptidis 200g, Radix Paeoniae Alba 400g, Fructus Mume 400g, Fructus Crataegi 400g
10 10 times of its weight water for medical material, reflux, extract, 2 times, each 1.5 hours.Extracting solution filters, and is evaporated to 1: 1, adds 90% ethanol to containing alcohol amount 68%, filters, and concentrating under reduced pressure becomes thick paste.80 ℃ of vacuum dryings, make dried cream powder.
Embodiment 9
Radix Trichosanthis 1000g, Radix Bupleuri 600g, Fructus Aurantii Immaturus 600g, Radix Et Rhizoma Rhei 250g, Rhizoma Pinelliae 300g, Radix Scutellariae 500g, Rhizoma Coptidis 300g, Radix Paeoniae Alba 500g, Fructus Mume 500g, Fructus Crataegi 300g
10 times of its weight water reflux, extract, 2 times each 1.5 hours for 10 medical materials, extracting solution filters, and is evaporated to 1: 1, adds 99% ethanol to containing alcohol amount 70%, filters, and concentrating under reduced pressure becomes thick paste.75 ℃ of vacuum dryings, make dried cream powder.
The preparation of embodiment 10 tablets
Prescription:
Pharmaceutical composition 100g of the present invention
Microcrystalline Cellulose 50g
Starch 100g
Carboxymethyl starch sodium 12g
The 5%PVP dehydrated alcohol is appropriate
Magnesium stearate 3g
Make 1000
Technique:
In pharmaceutical composition of the present invention and prescription, other adjuvant is crossed respectively 100 mesh sieves, taking recipe quantity pharmaceutical composition of the present invention adopts the equivalent method of progressively increasing to mix homogeneously with microcrystalline Cellulose, starch and carboxymethyl starch sodium, with appropriate PVP ethanol solution soft material processed, 14 mesh sieves are granulated, 50～60 ℃ of dryings 1 hour, add the 14 mesh sieve granulate for magnesium stearate of recipe quantity.
Get the special-shaped punch die tabletting of special rhombus for above-mentioned granule.
The preparation of embodiment 11 capsules
Prescription:
Pharmaceutical composition 100g of the present invention
Starch 200g
Carboxymethyl starch sodium 12g
The 5%PVP dehydrated alcohol is appropriate
Magnesium stearate 3g
Make 1000
Technique:
In pharmaceutical composition of the present invention and prescription, other adjuvant is crossed respectively 100 mesh sieves, taking recipe quantity pharmaceutical composition of the present invention adopts the equivalent method of progressively increasing to mix homogeneously with starch and carboxymethyl starch sodium, with appropriate PVP ethanol solution soft material processed, 14 mesh sieves are granulated, 50～60 ℃ of dryings 1 hour, add the 14 mesh sieve granulate for magnesium stearate of recipe quantity.
Getting above-mentioned granule incapsulates.
The preparation of embodiment 12 granules
Prescription:
Pharmaceutical composition 100g of the present invention
Micro-product cellulose 20g
Pulvis Talci 6g
3% polyvidone alcoholic solution is appropriate
Make 200 bags
Get pharmaceutical composition of the present invention and mix homogeneously with microcrystalline Cellulose, add 3% polyvidone alcoholic solution to make soft material, cross 18 mesh sieve granule processed, 50～60 ℃ of dryings 30～45 minutes, granulate, pack.
Claims (2)
1. the application of pharmaceutical composition in preparation protection islet function medicine,
This pharmaceutical composition is comprised of the raw medicinal herbs of following weight portion: Radix Bupleuri 3-30 part, Radix Paeoniae Alba 3-15 part, Fructus Aurantii Immaturus 3-15 part, Radix Et Rhizoma Rhei 1-6 part, Radix Scutellariae 3-15 part, Rhizoma Coptidis 1-12 part is characterized in that:
Described pharmaceutical composition is by weakening the expression of Fas antigen, and islet beta cell function is protected in the expression that strengthens FasL.
2. application claimed in claim 1 is characterized in that described pharmaceutical composition is comprised of the raw medicinal herbs of following weight portion: 9 parts of Radix Bupleuri, 15 parts of the Radix Paeoniae Albas, 9 parts of Fructus Aurantii Immaturuss, 3 parts of Radix Et Rhizoma Rhei, 9 parts of Radix Scutellariaes, 5 parts of Rhizoma Coptidis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810052992 CN101574424B (en) | 2008-05-05 | 2008-05-05 | Application of medicine combination in preparing medicament with function of protecting pancreatic island |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810052992 CN101574424B (en) | 2008-05-05 | 2008-05-05 | Application of medicine combination in preparing medicament with function of protecting pancreatic island |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101574424A CN101574424A (en) | 2009-11-11 |
| CN101574424B true CN101574424B (en) | 2013-11-06 |
Family
ID=41269584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810052992 Active CN101574424B (en) | 2008-05-05 | 2008-05-05 | Application of medicine combination in preparing medicament with function of protecting pancreatic island |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101574424B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116672415A (en) * | 2023-05-24 | 2023-09-01 | 大连医科大学附属第一医院 | Traditional Chinese medicine composition and traditional Chinese medicine preparation with effects of clearing heat, drying dampness, regulating qi and promoting qi stagnation and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726929A (en) * | 2004-07-30 | 2006-02-01 | 天津天士力制药股份有限公司 | Compsn. of medication for treating diabetes |
-
2008
- 2008-05-05 CN CN 200810052992 patent/CN101574424B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726929A (en) * | 2004-07-30 | 2006-02-01 | 天津天士力制药股份有限公司 | Compsn. of medication for treating diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101574424A (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011113190A1 (en) | Pharmaceutical composition for treating aids and preparation method thereof | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| CN101766737B (en) | Liver-soothing lipid-lowing drug composition and preparation method thereof | |
| CA3167884A1 (en) | Application of a traditional chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia | |
| CN101574424B (en) | Application of medicine combination in preparing medicament with function of protecting pancreatic island | |
| CN101574423B (en) | Application of medicine combination in preparing medicament for reducing insulin resistance | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN1943734B (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN102697771A (en) | New application of alpinetin | |
| CN102670956B (en) | Application of Chinese medicinal composition to preparation of anti-myocardial cell apoptosis and/or anti-myocardial cell apoptosis related disease drug | |
| CN107913277A (en) | The purposes of the anti-uric acid nephropathy of tanshinone | |
| CN101574391B (en) | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside | |
| CN101199606B (en) | Medicament for treating liver disease | |
| CN104740231A (en) | Pharmaceutical composition for treatment of qi-blood deficiency, irregular menstruation, metrorrhagia and leukorrheal diseases and preparation method thereof | |
| WO2017121333A1 (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN105944104B (en) | A kind of pharmaceutical composition for treating digestive tract ulcer | |
| CN104547499A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and atherosclerosis | |
| CN1315506C (en) | Chinese medicine preparation for treating gynecologic inflammation | |
| CN104435105B (en) | One kind is by Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, the pharmaceutical composition of dalbergia wood preparation | |
| CN102846711B (en) | 'Shen Gui ' capsule is preparing the application in antithrombotic reagent | |
| CN101574383A (en) | Prevention and treatment of diseases induced by microcirculation disturbance with panax notoginoside | |
| CN101357182B (en) | Medicine containing dark plum for treating diabetes and preparation method thereof | |
| CN100358558C (en) | Formulation for treating cardiovascular and cerebrovascular disease and its preparation process and quality control method | |
| CN100391513C (en) | Medicinal preparation for treating cardio and cerebral vascular disease and its preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TASLY PHARM. CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220608 Address after: 101-1032, F1, building 3, No. 103, Beiqing Road, Haidian District, Beijing 100081 Patentee after: Beijing zhongyitang Technology Co.,Ltd. Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |